Posts

Oral GLP-1 Tracker: Foundayo and Wegovy Pill Reach New Heights in Obesity Treatment Market

on

Mid-Year Healthcare Venture Trends to Watch in 2026

on

Novo sues Lilly over 'deceptive' ads comparing GLP-1 drug doses – key facts and context

on

Samsung Biologics Expands into Peptide API Manufacturing with $1.8B PolyPeptide Acquisition

on

Lilly bets $2.8B upfront on psychedelics in deal to buy AtaiBeckley

on

Eli Lilly partners with Oura to support GLP-1 patients via smart‑ring tools

on

Biopharma Job Market Report Q2 2026: Hiring Rebounds, Layoffs Ease, AI and R&D Talent in High Demand

on

Lilly Was Already Pharma’s Biggest Company. Now It’s Doing Deals to Match

on

Endevica spinout Kalohexis files confidential IPO to advance obesity drug rivaling GLP-1s

on

Villya Announces Breakthrough Data Demonstrating Enhanced Stability and Solubility for Insulin, GLP-1s

on

The Oral GLP-1 Tracker: Novo’s Wegovy keeps gaining ground in obesity market

on

Oral GLP‑1 Tracker: Novo’s oral Wegovy hits 3M prescription milestone as Lilly’s Foundayo chugs along in early launch

on

ADA: Metsera asset data support Pfizer’s entry point into obesity market

on

Lilly and Novo Face Off at ADA 2026 as Others Seek to Compete in Obesity

on

Hims & Hers Brings First-Time Access to Generic Semaglutide to Canada

on

Driven by GLP‑1s, Pharma’s Relationship with Consumers Is Starting to Change

on

Design Therapeutics’ Friedreich’s Ataxia Data and Vincentage’s Obesity Results from China

on

GLP-1 Patent Cliffs and Biotech M&A Surge in 2026

on

Novo Nordisk Q1: Pills, Pricing, Payments, Pressure

on

Obesity Drugs Overtake Oncology as Top Driver of Pharma R&D Returns: Deloitte Report

on